Rab5 is a small GTPase that regulates early endocytic events and is activated by RabGEF1/Rabex-5. Rabaptin-5, a Rab5 interacting protein, was identified as a protein critical for potentiating RabGEF1/Rabex-5's activation of Rab5. Using Rabaptin-5 shRNA knockdown, we show that Rabaptin-5 is dispensable for Rab5-dependent processes in intact mast cells, including 
Introduction
Mast cells are best known for their critical roles in IgE-associated immediate hypersensitivity reactions and other allergic disorders [1] [2] [3] [4] . IgE primes the mast cell to undergo Agdependent activation by binding to the high-affinity IgE receptor, FcεRI, a member of the immune receptor superfamily [1] [2] [3] [4] , and multivalent Ag initiates mast cell activation by crosslinking two or more FcεRI-bound IgE molecules that bind to that Ag. Mast cell activation induces a variety of responses including the release of preformed pro-inflammatory mediators (e.g., histamine, β-hexosaminidase) from the cytoplasmic granules, as well as the secretion of lipid mediators, cytokines, chemokines and growth factors [1] [2] [3] [4] .
Regulation of the expression of receptors and their downstream signaling pathways is critical for a cell to properly interpret and respond to the surrounding environment. Perturbations in these processes can have diverse and dramatic effects 5 . Receptor regulation is particularly important for mounting optimal responses to low concentrations of ligands, such as migration in response to chemotactic factors 6 or activation of secretion by Ags 3, 7 . Mast cells in particular are well known for being able to respond to small amounts of Ags [1] [2] [3] [4] . While many proteins have been identified that modulate receptor traffic to and from the cell surface, members of the Rab family of small GTPases have emerged as major regulators of many of these membrane trafficking events [8] [9] [10] [11] . Like all GTPases, Rabs cycle between GDP and GTP bound conformations, with the state of nucleotide binding dictating whether the Rab protein is active (GTP bound) or inactive (GDP bound). This nucleotide cycling is catalyzed by GEFs (guanine exchange factors; catalyze GTP binding) and GAPs (GTPase activating proteins;
stimulate Rabs intrinsic GTPase activity). Several of these Rab proteins have attracted much attention, including Rab5, the major regulator of early endocytic events, Rab4 and Rab11,
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Despite intense studies of their biochemistry, the functions of these proteins in regulating the activation and signaling of intact cells have only recently been investigated. In mast cells, Rab27a and Rab27b and its effectors 12, 13 regulate granule motility and degranulation, while the role of Rab3, initially reported to be important in regulating mast cell degranulaton 14 , remains to be fully clarified 15 .
We have shown that RabGEF1/Rabex-5 (RabGEF1), a Rab5 GEF, is critical for regulating the activation of mouse bone marrow-derived cultured mast cells (BMCMCs) [16] [17] [18] .
We demonstrated that mast cell activation by FcεRI cross-linking is regulated by RabGEF1's VPS9 domain which stimulates Rab5 activity, induces receptor internalization, and dampens excessive FcεRI-dependent mouse BMCMC activation 18 . A second RabGEF1 domain, the coiled-coil (CC) domain, although dispensable for FcεRI internalization or preventing excessive FcεRI-dependant activation, was essential to maintain high basal levels of FcεRI surface expression 18 . This domain also is the site of interaction between RabGEF1 and Rabaptin-5, a Rab5 effector 18, 19 , and this interaction is required to maintain high endogenous levels of Rabaptin-5 18 . The correlation that we observed between diminished FcεRI surface expression and decreased ability to maintain Rabaptin-5 levels in RabGEF1-deficient mast cells expressing a CC-deficient RabGEF1 mutant suggested that Rabaptin-5 may be important for regulating FcεRI trafficking and surface expression.
Although Rabaptin-5 has been proposed as an important Rab5 effector, there is uncertainty about its cellular role [20] [21] [22] [23] [24] . In our studies of the role of RabGEF1 in the regulation of intracellular signaling, we found that mast cells activated via IgE/FcεRI represented a tractable and informative model system for investigating such processes in intact cells 17, 18 . Given the Immunofluorescence. See SI. Briefly, BMCMCs were probed with the indicated primary antibodies: α-Rab5, α-EEA1 Abs (Santa Cruz Biotechnology, CA), α-FcεRIα (ebioscience), α-FcεRIβ, α-FcεRIγ, α-calnexin (Santa Cruz Biotechnology), α-GCC185 (S. Pfeffer, Stanford), α-LAMP1 (Iowa Developmental Studies Hybridoma Bank, IA), imaged at room temperature with the 63x Objective (N.A. 1.4) of a TCS SP5 confocal system (Leica, Germany) and processed with the Leica LAS Software. Single channel images were exported to Adobe Photoshop where whole image colors were balanced and images were cropped and overlaid for figures.
IL-6 ELISA. IL-6 ELISAs (BD Biosciences) were performed as described 16 . Adhesion assays. Were performed as described in 27 .
Flow cytometry (FC
Migration assays: Transwell BMCMC chemotaxis assays were performed as described previously 17 .
Quantitative-PCR. See SI.
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Results

Rabaptin-5 is dispensable for canonical Rab5 mediated processes
Rabaptin-5 is a Rab5 effector, but its function in intact cells remains elusive [21] [22] [23] . Rab5
regulates receptor internalization and early endosome sorting so it is possible that Rabaptin-5 may also be important for these roles. To examine Rabaptin-5's role in BMCMCs, we diminished Rabaptin-5 levels using lentivirally delivered Rabaptin-5 specific shRNA. There are many splice variants of Rabaptin-5, so we chose a target that would silence all forms 28 . Bis- Figure 1A) ; such cells could be maintained for at least 3 months in culture during which time the shR-treated BMCMCs continued to exhibit a substantial reduction in Rabaptin-5 protein levels (data not shown). RabGEF1 levels were unchanged ( Figure 1A ), even though we previously reported that the RabGEF1/Rabaptin-5 interaction was necessary to stabilize Rabaptin-5 protein levels 18 . The levels of other Rabaptin-5 interacting proteins such as Rab5, Rab4, GGA1, and γ-adaptin were also unchanged in the absence of Rabaptin-5 (Supplemental Figure 1A ).
In vitro and overexpression studies suggest that Rabaptin-5 is important for Rab5 activation, likely because of Rabaptin-5's ability to potentiate RabGEF1's activity 21, 23, 29 . To To assess if Rabaptin-5 can influence FcεRI transport to the surface, BMCMCs were fixed and total or surface FcεRI expression was examined by flow cytometry. Total FcεRI levels were similar in shC-or shR-treated BMCMCs ( Figure 2B ) whereas surface FcεRI levels in shRtreated BMCMCs were ~40% less than in control cells, suggesting that Rabaptin-5 may cause some intracellular accumulation of FcεRI. In accord with these findings, we detected no consistent differences between shR-and shC-treated BMCMCs FcεRI protein levels in total cell lysates as assessed by western blot (Supplemental Figure 1A) . Further, lower surface FcεRI levels in shR-treated BMCMCs were not due to decreased transcription, as FcεRIα mRNA levels were similar in the presence or absence of Rabaptin-5 (Supplemental Figure 1B) .
Rabaptin-5's putative function is to regulate membrane traffic [21] [22] [23] , so its absence may perturb FcεRI subcellular localization. The subcellular distribution of FcεRI in shC-and shR-treated BMCMCs was not obviously different ( Figure 2C ) although a large perinuclear accumulation of FcεRI was evident in both BMCMC groups (accounting for roughly 50-60% of the total FcεRI) that did not co-localize well with Rabaptin-5 or Rab5 ( Figure 2D ). Because
FcεRI is a heterotetramer composed of an α, β and two γ chains, we examined if the three subunits localized similarly within the cell and found that all subunits co-localized to surface and intracellular locations, suggesting that the detected FcεRIα localization reflects localization of the entire receptor complex (Supplemental Figure 3A) .
To characterize the intracellular FcεRI, we examined its distribution relative to a number of markers for the receptor biosynthetic route. Co-localization of FcεRI with the endoplasmic reticulum (ER) marker calnexin was minimal, suggesting that FcεRIα efficiently exits the ER found that Rab11 activity contributed to this process (Supplemental Figure 4) .
Rabpatin-5 increases FcεRI half-life
To investigate further the effect of Rabaptin-5 on FcεRI expression, we examined surface FcεRI levels by flow cytometry after treatment with the protein synthesis inhibitor cycloheximide Figure   4A ). Similarly, in BFA-treated cells, Rabaptin-5 deficiency reduced FcεRI half life from 2.8 (95% CI: 2.5-3.3) to 1.9 (95% CI: 1.6-2.4) hours ( Figure 4A ). Thus, no matter which approach was used to prevent new receptors from reaching the surface (i.e., blocking protein synthesis or exit from the ER), shR-treated BMCMCs were unable to maintain surface FcεRI as effectively as control cells. Consistent with these data, when the relative levels of FcεRI on the surface of shCor shR-treated BMCMCs before and after BFA or CHX treatment were compared, the differences between shC and shR-treated surface FcεRI increased as time elapsed (Figure 4B) demonstrating that the decreased FcεRI half-life in shR-treated BMCMCs significantly influences FcεRI surface levels.
Rabaptin-5 is dispensable for FcεRI recycling
FcεRI trafficking through a Rabaptin-5 regulated recycling route could explain how Rabaptin-5 influences FcεRI half-life. While there is evidence that FcεRI recycles 31, 34 , and the recycling of other immunoglobulin (Ig) receptors (FcγRI and FcRN) has been measured (recycling t 1/2 's of ~10 minutes) 35, 36 , we are not aware of such data for FcεRI recycling. We initially examined whether we could track FcεRI recycling with monomeric labeled IgE molecules, but we did not detect recycling of IgE-bound FcεRI complexes. Instead, we found that the IgE-bound FcεRI complexes that enter the cell often sort to Rab9 (late endosomal/lysosomal) positive compartments (Supplemental Figure 5) . 
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Rabaptin-5 deficiency did not alter the rate of FcεRI reappearance suggesting that Rabaptin-5 is dispensable for FcεRI recycling ( Figure 5B ). Further supporting the idea that Rabaptin-5 is not crucial for receptor recycling we found no differences in transferrin uptake or the rate of transferrin recycling in shC-or shR-treated BMCMCs, suggesting that Rabaptin-5 is not critical for transferrin recycling in primary mast cells ( Figure 5C ), consistent with findings in cell lines 23 .
Rabaptin-5 stabilizes cell-surface β1 integrin
In the absence of effects on transcription, subcellular localization and recycling, it is likely that the decreased FcεRI half-life in shR-treated BMCMCs reflects decreased FcεRI cell surface stability. If so, other receptors altered by Rabaptin-5 deficiency may have a similar defect in surface stability. β1 integrin recycles with high efficiency in a Rab11-dependent manner in a variety of cell lines 37 and is dramatically influenced by the loss of Rabaptin-5 ( Figure 2A ). We examined β1 integrin levels over time in shC-or shR-treated BMCMCs after exposure to vehicle or the endosome maturation/recycling inhibitor, primaquine (PQ). Although PQ rapidly diminished β1 integrin levels by 30 minutes in both shC-or shR-treated BMCMCs, shR-treated BMCMCs had a quicker and more substantial decrease in β1 integrin surface levels ( Figure 5D ).
This finding suggests that when recycling is inhibited, β1 integrin is removed more efficiently in the absence of Rabaptin-5.
In contrast, FcεRI surface levels decreased by only 15-20% in both shC-or shR-treated BMCMCs 30 minutes after exposure to PQ and returned to baseline by 1.5 hours (Supplemental Figure 6A ). This provides additional evidence that recycling of internalized FcεRI is minimal and is not influenced by Rabaptin-5. Notably, when new β1 integrin molecules were prevented from reaching the cell surface by exposing cells to CHX or BFA, Rabaptin-5-deficient cells
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From displayed a more precipitous reduction in β1 integrin surface expression over time than did control cells (Supplemental Figure 6B) as we observed for FcεRI (Figure 4) . Together, these data indicate that Rabaptin-5 is critical for FcεRI and β1 integrin cell surface stability.
Rabpatin-5 enhances mast cell functional responses to Ag
Do the reduced receptor levels in shR-treated BMCMCs have functional consequences?
Activation by specific Ag through FcεRI requires priming of the cells by IgE binding. We noted significantly less IgE bound to shR-treated BMCMCs after 24 hour culture with a range of IgE concentrations, with the most significant and substantial differences occurring at the lower IgE concentrations ( Figure 6A upper panel) . Notably, the fold increase in IgE association at higher concentrations was not different between shC-and shR-treated BMCMCs ( Figure 6A lower panel), suggesting a similar ability to upregulate FcεRI, probably due to the stabilizing effects of IgE on surface FcεRI 31, 33 . At the lowest IgE concentrations, similar to that in the blood of many subjects with allergic disorders 40 , shR-treated BMCMCs (which had lower levels of surface Having demonstrated that reduced FcεRI levels on mast cells with reduced levels of Rabaptin-5 resulted in less efficient IgE capture, we investigated whether mast cell functional activation by Ag induced cross linking of Ag-specific IgE/FcεRI complexes also was reduced by a deficiency of Rabaptin-5. The adhesion of shR-treated BMCMCs to fibronectin was markedly reduced in unstimulated cells and after low level exposure to specific Ag, while at high Ag concentration differences in adhesion between shC and shR-treated BMCMCs were minimal ( Figure 6D ). Similarly, in shR-treated BMCMC, Ag-induced migration ( Figure 6E ) and IL-6 production ( Figure 6F) were significantly impaired at a low Ag concentration, but not at 10-fold higher Ag concentrations. These data show that Rabaptin-5 deficiency can substantially alter mast cell sensitivity and responses to Ag, presumably at least in part because of the effects of the Rabaptin-5 deficiency on surface levels of FcεRI and β1 integrin.
Discussion
Our studies demonstrate that Rabaptin-5, a Rab5 effector, is important for maintaining surface expression of two important receptors in mast cells, FcεRI and β1 integrin. Contrary to the current thought based on in vitro studies, which have suggested that Rabaptin-5 is necessary to potentiate RabGEF1's activity, the data presented here (Figure 1) [44] [45] [46] , raising the possibility that Rabaptin-5 is involved in recycling or endosomal-Golgi traffic.
We found that Rabaptin-5 was dispensable for transferrin recycling ( Figure 5C ), the prototype for Rab4 recycling. FcεRI recycling, although minimal, was unaffected by the loss of Rabaptin-5 ( Figure 5B and Supplemental Figure 6A ). Furthermore, in our experiments in mast cells, the Rabaptin-5 interacting proteins GGA1 and AP-1 did not appear to be localized abnormally in the absence of Rabaptin-5 (Supplemental Figure 7) , even though others have
shown that over-expression of Rabaptin-5 alters the localization of GGA1 45 and AP-1 23 . Our findings of course do not exclude the possibility that Rabaptin-5 has a role in protein trafficking between the Golgi and endosomal compartments, but such a role remains to be demonstrated.
However, we did find a definite phenotypic abnormality in cells that lacked Rabaptin-5:
Rabaptin-5's absence diminished surface expression of certain BMCMC receptors under baseline conditions, demonstrating that Rabaptin-5 is necessary for maintaining normal levels of expression of these receptors on the cell surface. We found that FcεRIα transcription (Supplemental Figure 1B) and transport of FcεRI to the cell surface were unaffected by the loss of Rabaptin-5; both shC-and shR-treated BMCMCs upregulated FcεRI similarly when exposed to excess IgE, thus allowing stabilization of the vast majority of cell surface delivered FcεRI ( Figure 6A ). How then, does a lack of Rabaptin-5 alter levels of receptors on the cell surface?
Rabaptin-5 deficiency decreased FcεRI half-life in cells incubated without IgE by ~30%
( Figure 4A ). shR-treated BMCMCs also exhibited reduced upregulation of surface FcεRI upon internalization. An alternate explanation is that the reduced transferrin uptake may reflect reduced surface transferrin receptor levels, a phenomenon that was not specifically investigated 23 . In our system primary mast cells expressed very low levels of the transferrin receptor, so it was difficult to assess reliably any potential differences in surface expression of the receptor between control and Rabaptin-5-deficient mast cells.
Rabaptin-5 deficiency did not alter the intracellular distribution of a large trans-Golgi pool of FcεRI ( Figure 2C and 3B) , arguing against the possibility that Rabaptin-5 causes Figure   1A ) in shC-versus shR-treated BMCMCs. While it is possible that this may reflect a slight increase in FcεRIα mRNA levels in the absence of Rabaptin-5 (Supplemental Figure 1B) , that difference did not achieve statistical significance..
Our data reveal a novel and unpredicted function for Rabaptin-5 in increasing surface half-life of FcεRI and β1 integrin. However, the mechanism by which Rabaptin-5 enhances the surface half-life of these receptors is not clear. It is unlikely that Rabaptin-5 regulates Rab5 by altering the localization of either RabGEF1 or Rab5 because we found no obvious differences in the localization of RabGEF1-GFP, Rab5-GFP or endogenous Rab5 in shC-or shR-treated BMCMCs ( Figure 1B and 1C) . Figure 2A) . However, using a Cy5-BSA that was susceptible to internal quenching (and that is relieved from quenching during endosome maturation/acidification), we found that Rabaptin-5 deficient cells demonstrated a larger increase cell associated Cy5 fluorescence, ( Figure 1F ). This finding
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suggests that endosome acidification/maturation is enhanced in the absence of Rabaptin-5. While these preliminary data suggest that Rabaptin-5 regulates endosomal trafficking kinetics of fluid phase markers, a definitive mechanism for Rabaptin-5 in this process remains to be established.
Rabaptin-5 cleavage has been proposed as a mechanism that can disrupt the endosome compartment during apoptosis [47] [48] [49] . Although we found no differences in the viability of mast cells in standard culture media, Rabaptin-5-deficient BMCMCs were more susceptible to apoptosis after growth factor withdrawal (Supplemental Figure 8) . Future studies will be required to characterize in detail Rabaptin-5's role in cell survival.
In summary, we identified a novel role for Rabaptin-5 in increasing the surface stability of important mast cell receptors, and provided evidence that these changes contributed to the significant functional abnormalities observed in Rabaptin-5-deficient mast cells. The finding of diminished surface expression of FcεRI in Rabaptin-5-deficient mast cells is particularly important given the immunologic relevance of this receptor in allergic disorders and host defense. Some patients with moderate or severe asthma benefit from treatment with α-IgE, which reduces circulating IgE, IgE-dependent mast cell activation and allergic inflammation 50, 51 .
The data presented here are consistent with other evidence 52, 53 in suggesting that direct targeting of FcεRI also represents a promising approach for dampening unwanted mast cell activation.
Importantly, a better understanding of the regulation of FcεRI trafficking and surface expression regulation may provide insights about additional therapeutic alternatives. Our findings also highlight the incomplete knowledge about the Rab5 pathway. We provide evidence that, contrary to expectations, Rabaptin-5 is not necessary for canonical RabGEF1 activation of Rab5 or Rab5 processes in mast cells but instead may have a role in endosomal trafficking.
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